

LISTING OF CLAIMS

1. (Previously presented) An isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of TEM 17 as shown in SEQ ID NO: 230.
2. (Previously presented) The isolated molecule of claim 1 which is an intact antibody molecule.
3. (Original) The isolated molecule of claim 1 which is a single chain variable region (ScFv).
4. (Original) The isolated molecule of claim 1 which is a monoclonal antibody.
5. (Original) The isolated molecule of claim 1 which is a humanized antibody.
6. (Original) The isolated molecule of claim 1 which is a human antibody.
7. (Original) The isolated molecule of claim 1 which is bound to a cytotoxic moiety.
8. (Original) The isolated molecule of claim 1 which is bound to a therapeutic moiety.
9. (Original) The isolated molecule of claim 1 which is bound to a detectable moiety.
10. (Original) The isolated molecule of claim 1 which is bound to an anti-tumor agent.
- 11-17. (Cancelled)
18. (Previously presented) The isolated molecule of claim 4 which is bound to a cytotoxic moiety.
19. (Previously presented) The isolated molecule of claim 4 which is bound to a therapeutic moiety.
20. (Previously presented) The isolated molecule of claim 4 which is bound to a detectable moiety.
21. (Previously presented) The isolated molecule of claim 4 which is bound to an anti-tumor agent.

22. (Previously presented) The isolated molecule of claim 6 which is bound to a cytotoxic moiety.
23. (Previously presented) The isolated molecule of claim 6 which is bound to a therapeutic moiety.
24. (Previously presented) The isolated molecule of claim 6 which is bound to a detectable moiety.
25. (Previously presented) The isolated molecule of claim 6 which is bound to an anti-tumor agent.
26. (Previously presented) The isolated molecule of claim 1 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
27. (Previously presented) The isolated molecule of claim 2 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
28. (Previously presented) The isolated molecule of claim 3 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
29. (Previously presented) The isolated molecule of claim 4 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
30. (Previously presented) The isolated molecule of claim 5 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
31. (Previously presented) The isolated molecule of claim 6 wherein the antibody variable region specifically binds to residues 137-244 or 280-344 of TEM17.
32. (Previously presented) The isolated molecule of claim 1 wherein the antibody variable region specifically binds to residues 18-427 of TEM17.
33. (Previously presented) The isolated molecule of claim 2 wherein the antibody variable

region specifically binds to residues 18-427 of TEM17.

34. (Previously presented) The isolated molecule of claim 3 wherein the antibody variable region specifically binds to residues 18-427 of TEM17.

35. (Previously presented) The isolated molecule of claim 4 wherein the antibody variable region specifically binds to residues 18-427 of TEM17.

36. (Previously presented) The isolated molecule of claim 5 wherein the antibody variable region specifically binds to residues 18-427 of TEM17.

37. (Previously presented) The isolated molecule of claim 6 wherein the antibody variable region specifically binds to residues 18-427 of TEM17.